A semi-automated 2D/3D marker-based registration algorithm modelling prostate shrinkage during radiotherapy for prostate cancer

Radiotherapy and Oncology

Volumn 90, Issue 3, 2009, Pages 331-336

  Budiharto, Tom ^a,b   Slagmolen, Pieter ^a   Hermans, Jeroen ^a   Maes, Frederik ^a   Verstraete, Jan ^a   Heuvel, Frank Van den ^a   Depuydt, Tom ^a   Oyen, Raymond ^a   Haustermans, Karin ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b LKI   (Belgium)

Author keywords

Fiducial markers; Prostate cancer; Prostate shrinkage; Radiotherapy; Semi automated 2D 3D registration algorithm

Indexed keywords

ANDROGEN; TUMOR MARKER;

ALGORITHM; ARTICLE; AUTOMATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SIZE; THREE DIMENSIONAL IMAGING;

ADENOCARCINOMA; ALGORITHMS; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; GOLD; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; MODELS, THEORETICAL; PROSTATE; PROSTATIC NEOPLASMS;

EID: 61349197485     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.10.007     Document Type: Article

References (29)

1. Beaulieu L., Girouard L.M., Aubin S., et al. Performing daily prostate targeting with a standard V-EPID and an automated radio-opaque marker detection algorithm. Radiother Oncol 73 (2004) 61-64
2. D'Amico A.V., Manola J., Loffredo M., Renshaw A.A., DellaCroce A., and Kantoff P.W. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821-827
3. Fiorino C., Cozzarini C., Vavassori V., et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 64 (2002) 1-12
4. Harris E.J., McNair H.A., and Evans P.M. Feasibility of fully automated detection of fiducial markers implanted into the prostate using electronic portal imaging: a comparison of methods. Int J Radiat Oncol Biol Phys 66 (2006) 1263-1270
5. Hermans J, Depuydt T, Maes F, Van den Heuvel F, Haustermans K, Suetens PA. framework for the analysis of marker-based 2D/3D registration applied in patient alignment for radiotherapy of prostate tumors. Technical Report KUL/ESAT/PSI/0602 2006 Nov. Available from: .
6. Jackson A., Skwarchuk M.W., Zelefsky M.J., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 49 (2001) 685-698
7. Kim Y., Hsu I.-C., Lessard E., Vujic J., and Pouliot J. Dosimetric impact of prostate volume change between CT-based HDR brachytherapy fractions. Int J Radiat Oncol Biol Phys 59 (2004) 1208-1216
8. Koper P.C., Jansen P., van Putten W.L., et al. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial. Radiother Oncol 73 (2004) 1-9
9. Kupelian P.A., Willoughby T.R., Meeks S.L., et al. Intraprostatic fiducials for localization of the prostate gland: monitoring intermarker distances during radiation therapy to test for marker stability. Int J Radiat Oncol Biol Phys 62 (2005) 1291-1296
10. Langen K.M., and Jones D.T. Organ motion and its management. Int J Radiat Oncol Biol Phys 50 (2001) 265-278
11. Mechalakos J.G., Mageras G.S., Zelefsky M.J., et al. Time trends in organ position and volume in patients receiving prostate three-dimensional conformal radiotherapy. Radiother Oncol 62 (2002) 261-265
12. Nederveen A.J., Dehnad H., van der Heide U.A., van Moorselaar R.J., Hofman P., and Lagendijk J.J. Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials. Radiother Oncol 68 (2003) 81-88
13. Nichol A.M., Brock K.K., Lockwood G.A., et al. A magnetic resonance imaging study of prostate deformation relative to implanted gold fiducial markers. Int J Radiat Oncol Biol Phys 67 (2007) 48-56
14. Nichol A.M., Rosewall T., Catton C.N., Jaffray D.A., and Warde P.R. Intra-prostatic fiducial markers and concurrent androgen deprivation. Clin Oncol (R Coll Radiol) 17 (2005) 465-468
15. Nuyttens J.J., Milito S., Rust P.F., and Turrisi A.T. III. Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. Radiother Oncol 64 (2002) 209-214
16. Pan CC, Sandler HM, Levine LL, et al. Targeting the prostate with external beam radiotherapy: prostate volume changes and their relationship to implantable markers [abstract 92]. 2005 ASCO Prostate Cancer Symposium; Orlando; Fl.
17. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
18. Poggi M.M., Gant D.A., Sewchand W., and Warlick W.B. Marker seed migration in prostate localization. Int J Radiat Oncol Biol Phys 56 (2003) 1248-1251
19. Pollack A. What's your position? We have a need to know. Int J Radiat Oncol Biol Phys 43 (1999) 705-706
20. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
21. Pouliot J., Aubin M., Langen K.M., et al. (non)-Migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys 56 (2003) 862-866
22. Sanguineti G., Marcenaro M., Franzone P., Foppiano F., and Vitale V. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy. Radiother Oncol 66 (2003) 151-157
23. Schallenkamp J.M., Herman M.G., Kruse J.J., and Pisansky T.M. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys 63 (2005) 800-811
24. Van den Heuvel F., Fugazzi J., Seppi E., and Forman J.D. Clinical application of a repositioning scheme, using gold markers and electronic portal imaging. Radiother Oncol 79 (2006) 94-100
25. Waterman F.M., Yue N., Reisinger S., Dicker A., and Corn B.W. Effect of edema on the post-implant dosimetry of an I-125 prostate implant: a case study. Int J Radiat Oncol Biol Phys 38 (1997) 335-339
26. Wu J., Haycocks T., Alasti H., et al. Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol 61 (2001) 127-133
27. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55 (2000) 241-249
28. Zelefsky M.J., and Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 49 (1997) 38-45
29. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239